Akèy › Obèsite › North Carolina › Wilmington
Etid klinik pou Obèsite nan Wilmington, NC
15 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Wilmington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Accellacare - Tradd Court - Wilmington /ID# 282200, Wilmington
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Ap rekriteFaz 3
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Ap rekriteFaz 2
- TMA Headlands, Wilmington
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
- Accellacare and KDCILM, LLC, Wilmington
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
- Accellacare and KDCILM, LLC, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Ap rekriteFaz 3
- Accellacare - Wilmington - 1917 Tradd Court, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Ap rekriteFaz 3
- Accellacare of Wilmington, Wilmington
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Ap rekriteFaz 3
- KDCILM, LLC & Accellacare US, Inc., Wilmington
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Ap rekriteFaz 3
- Accellacare Research of Wilmington, Wilmington
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- Accellacare Wilmington, Wilmington
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Wilmington
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Ap rekriteFaz 2
- Accellacare of Wilmington, Wilmington
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Ap rekriteFaz 3
- Accellacare and KDCILM, LLC, Wilmington
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Ap rekriteFaz 1
- Accellacare, Wilmington
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL32 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Las Vegas, NV27 etid
- Miami, FL27 etid
- Baltimore, MD26 etid
- Jacksonville, FL25 etid
Lòt etid nan Wilmington
- Sipwa11 etid
- Dyabèt Tip 28 etid
- Ensifizyans kadyak6 etid
- Kolit Ulseratif4 etid
- Kolestewòl3 etid
- Maladi kadyovaskilè3 etid
- Hypertension artérielle3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.